Literature DB >> 10661569

Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications.

G Romano1, P Michell, C Pacilio, A Giordano.   

Abstract

Over the last decade, more than 300 phase I and phase II gene-based clinical trials have been conducted worldwide for the treatment of cancer and monogenic disorders. Lately, these trials have been extended to the treatment of AIDS and, to a lesser extent, cardiovascular diseases. There are 27 currently active gene therapy protocols for the treatment of HIV-1 infection in the USA. Preclinical studies are currently in progress to evaluate the possibility of increasing the number of gene therapy clinical trials for cardiopathies, and of beginning new gene therapy programs for neurologic illnesses, autoimmuno diseases, allergies, regeneration of tissues, and to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as genetic immunization. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission to individuals who are at risk of infection. Research programs have also been considered to develop therapeutic vaccines for patients with AIDS and generate either preventive or therapeutic vaccines against malaria, tuberculosis, hepatitis A, B and C viruses, influenza virus, La Crosse virus, and Ebola virus. The potential therapeutic applications of gene transfer technology are enormous. However, the effectiveness of gene therapy programs is still questioned. Furthermore, there is growing concern over the matter of safety of gene delivery and controversy has arisen over the proposal to begin in utero gene therapy clinical trials for the treatment of inherited genetic disorders. From this standpoint, despite the latest significant achievements reported in vector design, it is not possible to predict to what extent gene therapeutic interventions will be effective in patients, and in what time frame.

Entities:  

Mesh:

Year:  2000        PMID: 10661569     DOI: 10.1634/stemcells.18-1-19

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  16 in total

Review 1.  Gene therapy for brain tumors.

Authors:  K Bansal; H H Engelhard
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Stem cell transplantation.

Authors:  A L Lennard; G H Jackson
Journal:  BMJ       Date:  2000-08-12

3.  A model for antimicrobial gene therapy: demonstration of human beta-defensin 2 antimicrobial activities in vivo.

Authors:  George T-J Huang; Hai-Bo Zhang; Daniel Kim; Lide Liu; Tomas Ganz
Journal:  Hum Gene Ther       Date:  2002-11-20       Impact factor: 5.695

Review 4.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

5.  Anionic liposomal delivery system for DNA transfection.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2004-10-15       Impact factor: 4.009

6.  Characterization of five evolutionary conserved regions of the human tyrosine hydroxylase (TH) promoter: implications for the engineering of a human TH minimal promoter assembled in a self-inactivating lentiviral vector system.

Authors:  Gaetano Romano; Sokreine Suon; Hao Jin; Angela E Donaldson; Lorraine Iacovitti
Journal:  J Cell Physiol       Date:  2005-08       Impact factor: 6.384

7.  Liposome-mediated functional expression of multiple drug resistance gene in human bone marrow CD34+ cells.

Authors:  Wenjing Cao; Ping Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

Review 8.  Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?

Authors:  Alfredo Fucito; Chiara Lucchetti; Antonio Giordano; Gaetano Romano
Journal:  Int J Biochem Cell Biol       Date:  2007-10-23       Impact factor: 5.085

9.  Characterization of a neuraminidase-deficient influenza a virus as a potential gene delivery vector and a live vaccine.

Authors:  Kyoko Shinya; Yutaka Fujii; Hiroshi Ito; Toshihiro Ito; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Human β-defensin-2 gene transduction of dental pulp cells: A model for pulp antimicrobial gene therapy.

Authors:  George T-J Huang; Hai-Bo Zhang; Chunyi Yin; Sang Hyuk Park
Journal:  Int J Oral Biol       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.